US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
biotech · PTSD - Post Traumatic Stress Disorder · P1b: Advanced Solid Tumors · CMPX
Compass Therapeutics
Compass Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
80 Guest Street, Suite 601, Boston, MA 02135, US HQ
2014 Founded
54 Employees
Public company Type
CMPX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 80 Guest Street, Suite 601, Boston, MA 02135, US
- Founded
- 2014
- Employees
- 54
- Programs
- 15
- Drugs
- 3
- Patents
- 100
Compass Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Compass Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Compass Therapeutics in public FDA and regional records.
-
Development asset linked to Compass Therapeutics in public FDA and regional records.